Merrimack Pharmaceuticals Initiates Enrollment In A Phase 1/2 Combination Study Of MM-121 And Tarceva In Patients With Non-Small Cell Lung Cancer
Merrimack Pharmaceuticals, Inc. announced that the first patient has received an initial dose in a Phase 1/2 clinical study combining MM-121 with Tarceva?? (erlotinib) in patients with non- small cell lung cancer (NSCLC). This is the first of multiple trials that Merrimack and sanofi-aventis expect to initiate in 2010 as part of a broad Phase 2 clinical development program for MM-121. Source: General Cancer News Articles Provided by Cancer Compass
